Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer

NCT00625846 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00625846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00625846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
February 22, 2008
Completion date
August 13, 2019
Enrollment
152 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent thyroid gland carcinoma, stage iii differentiated thyroid gland carcinoma ajcc v7, stage iii thyroid gland medullary carcinoma ajcc v7, stage iva differentiated thyroid gland carcinoma ajcc v7, stage iva thyroid gland anaplastic carcinoma ajcc v7, stage iva thyroid gland medullary carcinoma ajcc v7, stage ivb differentiated thyroid gland carcinoma ajcc v7, stage ivb thyroid gland anaplastic carcinoma ajcc v7, stage ivb thyroid gland medullary carcinoma ajcc v7, stage ivc differentiated thyroid gland carcinoma ajcc v7, stage ivc thyroid gland anaplastic carcinoma ajcc v7, stage ivc thyroid gland medullary carcinoma ajcc v7, thyroid gland anaplastic carcinoma